• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study
CONCLUSIONS: Our results indicated no evidence of an increased ischemic or bleeding risk after vaccination with inactivated SARS-CoV-2 vaccine among Chinese patients with CAD, with limited statistical power.PMID:36756815 | DOI:10.1093/cvr/cvad031
Source: Atherosclerosis - February 9, 2023 Category: Cardiology Authors: Huajie Xu Jiaojiao Zheng Xin Zhao Qi Zhou Bing Fan Hongyi Wu Si Zhang Junbo Ge Source Type: research

The 3rd Beijing Forum of Evidence-Based Medicine and 2023 Cochrane China Network Symposium successfully held
Cochrane China recently hosted a virtual event for the evidence-based medicine community that brought together many of its partners, local expertise, and international speakers. Here the team provides an overview of who was involved and what was covered at the event.  The3rd Beijing forum of evidence-based medicine and Cochrane China Network  Symposium was successfully held virtually on January 15th, 2023. The host of this conference wereCochrane China Network and Beijing GRADE Center. The organizers are Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, affiliate of the Cochrane China Ne...
Source: Cochrane News and Events - February 17, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news

The contribution  of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
ConclusionsGenotype-guided selection of P2Y12 inhibitor made a very positive contribution on the prognosis in Chinese ACS/CCS patients undergoing PCI. Instead of intensifying antiplatelet strategies, conventional-dose clopidogrel could be recommended as P2Y12 inhibitor after weighing MACEs and bleeding events in CYP2C19 IM patients.
Source: European Journal of Clinical Pharmacology - July 14, 2023 Category: Drugs & Pharmacology Source Type: research

Pages: 1  2  3  4  5  6  7  8